CGTLive®’s Weekly Rewind – May 30, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

The patient’s death occurred after an acute systemic infection and was associated with an unexpected SAE of clinical complications related to a capillary leak syndrome.

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

In observance of ALS Awareness Month, held annually in May, we took a look at the clinical pipeline of advanced therapeutics currently in development for the neurodegenerative disease.

Roger Hajjar, MD, the director of the Mass General Brigham Gene and Cell Therapy Institute, also discussed the Institute’s presentations at ASGCT’s 2025 conference.

Alongside the announcement, Ocugen noted that it intends to initiate a phase 2/3 confirmatory clinical trial for OCU410ST in the coming weeks.